The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma

Cancer Research

Volumn 63, Issue 13, 2003, Pages 3695-3700

  Heliström, Ingegerd ^a   Raycraft, John ^a   Hayden Ledbetter, Martha ^a   Ledbetter, Jeffrey A ^a   Schummer, Michèl ^b,e   McIntosh, Martin ^c   Drescher, Charles ^c,d   Urban, Nicole ^c   Hellström, Karl Erik ^a  

^a PACIFIC NORTHWEST RESEARCH INSTITUTE   (United States)

^b INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d SWEDISH MEDICAL CENTER   (United States)

^e Analytical Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; GENE PRODUCT; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G2A; MONOCLONAL ANTIBODY; PROTEIN HE4; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FUSION GENE; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HYBRIDOMA; MAMMAL CELL; MULTIGENE FAMILY; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN PURIFICATION; SENSITIVITY AND SPECIFICITY;

EPIDIDYMAL SECRETORY PROTEINS; FEMALE; GENE AMPLIFICATION; HUMANS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PILOT PROJECTS; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0038756386     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Ries, L. A. G., Kosary, C. L., Hankey, B. F., Miller, B. A., Clegg, L., and Edwards, B. K. SEER Cancer Statistics Review. National Cancer Institute.
2. Jacobs, I., and Bast, R. C. The CA-125 tumour associated antigen: a review of the literature. Hum. Reprod., 4: 1-12, 1989.
3. Berek, J. S., and Bast, R. C., Jr. Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Cancer, 76: 2092-2096, 1995.
4. Maggino, T., Gadducci, A., D'Addario, V., Pecorelli, S., Lissoni, A., Stella, M., Romagnolo, C., Federghini, M., Zucca, S., Trio, D., et al. Prospective multicenter study on CA 125 in postmenopausal pelvic masses. Gynecol. Oncol., 54: 117-123, 1994.
5. Chang, K., Pai, L. H., Batra, J. K., Pastan, I., and Willingham, M. C. Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium. Cancer Res., 52: 181-186, 1992.
6. Kojima, T., Oh-eda, M., Hattori, K., Taniguchi, Y., Tamura, M., Ochi, N., and Yamaguchi, N. Molecular cloning and expression of megakaryocyte potentiating factor cDNA. J. Biol. Chem., 270: 21984-21990, 1995.
7. Scholler, N., Fu, N., Yang, Y., Ye, Z., Goodman, G., Hellstrom, K., and Hellstrom, I. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc. Natl. Acad. Sci. USA, 96: 11531-11536, 1999.
8. Schummer, M., Ng, W., Bumgarner, R., Nelson, P., Schummer, B., Bednarski, D., Hassell, L., Baldwin, R., Karlan, B., and Hood, L. Comparative hybridization of an array of 21 500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene, 238: 375-385, 1999.
9. Wang, K., Gan, L., Jeffrey, E., Gayle, M., Gown, A. M., Skelly, M., Nelson, P. S., Ng, W., Schummer, M., Hood, L., and Mulligan, J. Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray. Gene, 229: 101-108, 1999.
10. Hough, C. D., Sherman-Baust, C. A., Pizer, E. S., Montz, F. J., Im, D. D., Rosenshein, N. B., Cho, K. R., Riggins, G. J., and Morin, P. J. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res., 60: 6281-6287, 2000.
11. Ismail, R. S., Baldwin, R. L., Fang, J., Browning, D., Karlan, B. Y., Gasson, J. C., and Chang, D. D. Differential gene expression between normal and tumor-derived ovarian epithelial cells. Cancer Res., 60: 6744-6749, 2000.
12. Martoglio, A. M., Tom, B. D., Starkey, M., Corps, A. N., Charnock-Jones, D. S., and Smith, S. K. Changes in tumorigenesis- and angiogenesis-related gene transcript abundance profiles in ovarian cancer detected by tailored high density cDNA arrays. Mol. Med., 6: 750-765, 2000.
13. Ono, K., Tanaka, T., Tsunoda, T., Kitahara, O., Kihara, C., Okamoto, A., Ochiai, K., Takagi, T., and Nakamura, Y. Identification by cDNA microarray of genes involved in ovarian carcinogenesis. Cancer Res., 60: 5007-5011, 2000.
14. Welsh, J. B., Zarrinkar, P. P., Sapinoso, L. M, Kern, S. G., Behling, C. A., Monk, B. J., Lockhart, D. J., Burger, R. A., and Hampton, G. M. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc. Natl. Acad. Sci. USA, 98: 1176-1181, 2001.
15. Kirchhoff, C., Habben, I., Ivell, R., and Krull, N. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol. Reprod., 45: 350-357, 1991.
16. Kirchhoff, C. Molecular characterization of epididymal proteins. Rev. Reprod., 3: 86-95, 1998.
17. Dandekar, A. M., Robinson, E. A., Appellla, E., and Quasba, P. K. Complete sequence analysis of cDNA clones encoding rat whey phosphoprotein: homology to a protease inhibitor. Proc. Natl. Acad. Sci. USA, 79: 3987-3991. 1982.
18. Heinzel, R., Appelhans, H., Gassen, G., Seemuler, U., Machleidt, W., Fritz, H., and Steffens, G. Molecular cloning and expression of cDNA for human antileukoprotease from cervix uterus. Eur. J. Biochem., 160: 61-67, 1986.
19. Wiedow, O., Schroder, J. M., Gregory, H., Young, J. A., and Christophers, E. Elafin: an elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence. J. Biol. Chem., 265: 14791-14795, 1990.
20. Bingle, L., Singleton, V., and Bingle, C. D. The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene, 21: 2768-2773, 2002.
21. Hayden, M. S., Gilliland, L. K., and Ledbetter, J. A. Antibody engineering. Curr. Opin. Immunol., 9: 201-212, 1997.
22. Kirchhoff, C., and Willison, K. Nucleotide and amino-acid sequence of human testis-derived TCP1. Nucleic Acids Res., 18: 4247, 1990.
23. Hayden, M. S., Linsley, P. S., Gayle, M. A., Bajorath, J., Brady, W. A., Norris, N. A., Fell, H. P., Ledbetter, J. A., and Gilliland, L. K. Single-chain mono- and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system. Ther. Immunol., 1: 3-15, 1994.
24. Hellstrom, I., Goodman, G., Pullman, J., Yang, Y., and Hellstrom, K. E. Overexpression of HER-2 in ovarian carcinomas. Cancer Res., 61: 2420-2423, 2001.
25. Capon, D. J., Chamow, S. M, Mordenti, J., Marsters, S. A., Gregory, T., Mitsuya, H., Byrn, R. A., Lucas, C., Wurm, F. M., Groopman, J. E., et al. Designing CD4 immunoadhesins for AIDS therapy. Nature, 337: 525-531, 1989.
26. Hayden, M. S., Grosmaire, L. S., Norris, N. A., Gilliland, L. K., Winberg, G., Tritschler, D., Tsu, T. T., Linsley, P. S., Mittler, R. S., Senter, P. D., Fell, H. P., and Ledbetter, J. A. Costimulation by CD28 sFv expressed on the tumor cell surface or as a soluble bispecific molecule targeted to the L6 carcinoma antigen. Tissue Antigens, 48: 242-254, 1996.
27. Urlaub, G., Mitchell, P. J., Kas, E., Chasin, L. A., Funanage, V. L., Myoda, T. T., and Hamlin, J. Effect of gamma rays at the dihydrofolate reductase locus: deletions and inversions. Somatic Cell Mol. Genet., 12: 555-566, 1986.
28. Barsoum, J. Introduction of stable high-copy-number DNA into Chinese hamster ovary cells by electroporation. DNA Cell Biol., 9: 293-300, 1990.
29. Hanley, J. A., and McNeil, B. J. The meaning and use of the area under the receiver operating characteristic (roc) curve. Radiology, 143: 23-29, 1982.
30. Pepe, M. S. An interpretation for the ROC curve and inference using GLM procedures. Biometrics, 56: 352-359, 2000.
31. Pepe, M. S. Receiver operating characteristics methodology. J. Am. Stat. Assoc., 95: 308-311, 2000.
32. Jacobs, I. Overview-progress in screening for ovarian cancer. In: F. Sharp, T. Blackett, J. Berek, and R. Bast (eds.), Ovarian Cancer, Vol. 5, pp. 173-185. Oxford: ISIS Medical Media, 1998.